ReviewFrontiers in psychiatry2025
MRI-based insights into brain structural and functional alterations in schizophrenia treated with risperidone.
Review in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal neuroimaging alterations in schizophrenia model rats and the modulatory effects of risperidone: a pilot study.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schizophrenia (SZ) is a severe psychiatric disorder, with antipsychotics serving as the primary treatment. Among them, risperidone plays a crucial role in alleviating both positive and negative symptoms while also enhancing cognitive function. Advances in magnetic resonance imaging (MRI) technology have provided an effective means of investigating the effects of risperidone on the brain, particularly in terms of neural pathways, therapeutic efficacy, and predictive outcomes. This review offers a summary of current findings on the impact of risperidone treatment on gray matter, white matter, and functional brain activity and connectivity in SZ patients, including its neural mechanisms, therapeutic benefits, and potential side effects. Methods: Literatures on the use of risperidone for treating schizophrenia were searched in PubMed, Embase and Web of Science analyzing and summarizing the alterations in brain structure and function associated with risperidone. Results: Through the analysis and summary, it was found that risperidone treatment in SZ patients can have a marked effect on different structural and functional regions including the prefrontal lobe, temporal lobe, cingulate gyrus, corona radiata, basal ganglia, and corpus callosum. Conclusion: Most research has focused on short-term effects, with limited longitudinal data to assess long-term efficacy and side effects, more researches could be added in the future. In addition, more potential methods such as DKI, DSI and brain covariance network have the opportunity to be used in the study of brain structure and function in the treatment of schizophrenia with risperidone in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.